1
|
Synthesis and Application of Albumin Nanoparticles Loaded with Prussian Blue Nanozymes. COLLOIDS AND INTERFACES 2022. [DOI: 10.3390/colloids6020029] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Prussian blue nanozymes exhibit peroxidase-like catalytic activity and are therefore considered a stable and inexpensive alternative to natural peroxidases in the enzyme-linked immunosorbent assay (ELISA). In this work, we propose a robust method of Prussian blue nanozyme functionalization, which relies on the entrapment of nanozymes into albumin nanoparticles. The principle of the method is the addition of ethanol to a solution that contains albumin and nanozymes. At a high ethanol concentration solubility of albumin decreases, resulting in the formation of albumin nanoparticles loaded with nanozymes. The hydrodynamic diameter of nanoparticles was between 120 and 230 nm and depended on the nanozyme-to-BSA ratio. Encapsulation efficiency of nanozymes reached 96–99% and up to 190 μg of nanozymes were loaded per 1 mg of nanoparticles. Nanoparticles were stable at pH 5.5–7.5 and upon long-term storage in deionized water. Excellent reproducibility of the synthesis procedure was confirmed by the preparation of three individual batches of Prussian-blue-loaded BSA nanoparticles with almost identical properties. Nanoparticles were functionalized with monoclonal antibodies using glutaraldehyde cross-linking. The resulting conjugates were applied as labels in an ELISA-like assay of tumor marker prostate-specific antigen (PSA). The lower limit of detection was below 1 ng/mL, which enables measurement of PSA in the range of clinically relevant concentrations.
Collapse
|
2
|
Iván Martínez-Muñoz O, Elizabeth Mora-Huertas C. Nanoprecipitation technology to prepare carrier systems of interest in pharmaceutics: An overview of patenting. Int J Pharm 2022; 614:121440. [PMID: 34998924 DOI: 10.1016/j.ijpharm.2021.121440] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 11/07/2021] [Accepted: 12/28/2021] [Indexed: 10/19/2022]
Abstract
Nanoprecipitation is a practical method to prepare carriers at the nanometric scale, which attracts attention in pharmaceutics because of its low cost, easy setup, the versatility of the starting materials, possibility to obtain different kinds of carriers, and minimal environmental impact. Since 1986, this technique has been extensively employed in research; therefore, this paper focuses on state of art regarding inventions wherein it is employed. To this end, 133 nanoprecipitation-based patent families are identified in the PatSnap® platform, which allows identifying general trends. Afterwards, a sample of 40 patent families reported as granted (21 families) or patent applications (19 families) during the last decade are studied in depth to establish the research tendencies. Undoubtedly, Chinese universities are positioned as leaders in this field, and cancer treatments are the more claimed use followed far behind for developments targeting neurodegenerative and diabetes diseases. New proposals on targeted and stimuli response particles are also claimed, and development of polymers, prodrugs, and improvements to the technique such as the flash-nanoprecipitation, use of microfluidics, or design of green process are relevant. Interestingly, nanoprecipitation-related patent families have significantly increased during the last decade, being the 71% of the total, which makes alluring the perspectives about its industrial harnessing.
Collapse
Affiliation(s)
- Oscar Iván Martínez-Muñoz
- Universidad Nacional de Colombia. Sede Bogotá. Facultad de Ciencias. Departamento de Farmacia. Ciudad Universitaria, Carrera 30 45-03, Edificio 450, Bogotá, postal code 111321, Colombia
| | - Claudia Elizabeth Mora-Huertas
- Universidad Nacional de Colombia. Sede Bogotá. Facultad de Ciencias. Departamento de Farmacia. Ciudad Universitaria, Carrera 30 45-03, Edificio 450, Bogotá, postal code 111321, Colombia.
| |
Collapse
|
3
|
Mast MP, Modh H, Champanhac C, Wang JW, Storm G, Krämer J, Mailänder V, Pastorin G, Wacker MG. Nanomedicine at the crossroads - A quick guide for IVIVC. Adv Drug Deliv Rev 2021; 179:113829. [PMID: 34174332 DOI: 10.1016/j.addr.2021.113829] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 05/17/2021] [Accepted: 06/10/2021] [Indexed: 02/08/2023]
Abstract
For many years, nanomedicine is pushing the boundaries of drug delivery. When applying these novel therapeutics, safety considerations are not only a key concern when entering clinical trials but also an important decision point in product development. Standing at the crossroads, nanomedicine may be able to escape the niche markets and achieve wider acceptance by the pharmaceutical industry. While there is a new generation of drug delivery systems, the extracellular vesicles, standing on the starting line, unresolved issues and new challenges emerge from their translation from bench to bedside. Some key features of injectable nanomedicines contribute to the predictability of the pharmacological and toxicological effects. So far, only a few of the physicochemical attributes of nanomedicines can be justified by a direct mathematical relationship between the in vitro and the in vivo responses. To further develop extracellular vesicles as drug carriers, we have to learn from more than 40 years of clinical experience in liposomal delivery and pass on this knowledge to the next generation. Our quick guide discusses relationships between physicochemical characteristics and the in vivo response, commonly referred to as in vitro-in vivo correlation. Further, we highlight the key role of computational methods, lay open current knowledge gaps, and question the established design strategies. Has the recent progress improved the predictability of targeted delivery or do we need another change in perspective?
Collapse
|
4
|
Khramtsov P, Kalashnikova T, Bochkova M, Kropaneva M, Timganova V, Zamorina S, Rayev M. Measuring the concentration of protein nanoparticles synthesized by desolvation method: Comparison of Bradford assay, BCA assay, hydrolysis/UV spectroscopy and gravimetric analysis. Int J Pharm 2021; 599:120422. [PMID: 33647407 DOI: 10.1016/j.ijpharm.2021.120422] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 02/04/2021] [Accepted: 02/21/2021] [Indexed: 12/12/2022]
Abstract
The desolvation technique is one of the most popular methods for preparing protein nanoparticles for medicine, biotechnology, and food applications. We fabricated 11 batches of BSA nanoparticles and 2 batches of gelatin nanoparticles by desolvation method. BSA nanoparticles from 2 batches were cross-linked by heating at +70 °C for 2 h; other nanoparticles were stabilized by glutaraldehyde. We compared several analytical approaches to measuring their concentration: gravimetric analysis, bicinchoninic acid assay, Bradford assay, and alkaline hydrolysis combined with UV spectroscopy. We revealed that the cross-linking degree and method of cross-linking affect both Bradford and BCA assay. Direct measurement of protein concentration in the suspension of purified nanoparticles by dye-binding assays can lead to significant (up to 50-60%) underestimation of nanoparticle concentration. Quantification of non-desolvated protein (indirect method) is affected by the presence of small nanoparticles in supernatants and can be inaccurate when the yield of desolvation is low. The reaction of cross-linker with protein changes UV absorbance of the latter. Therefore pure protein solution is an inappropriate calibrator when applying UV spectroscopy for the determination of nanoparticle concentration. Our recommendation is to determine the concentration of protein nanoparticles by at least two different methods, including gravimetric analysis.
Collapse
Affiliation(s)
- Pavel Khramtsov
- Department of Biology, Perm State University, 614068, 15 Bukirev str., Perm, Russia; Institute of Ecology and Genetics of Microorganisms, Perm Federal Research Center of the Ural Branch of the Russian Academy of Sciences, 614081, 13 Golev str., Perm, Russia.
| | - Tatyana Kalashnikova
- Department of Biology, Perm State University, 614068, 15 Bukirev str., Perm, Russia; Institute of Ecology and Genetics of Microorganisms, Perm Federal Research Center of the Ural Branch of the Russian Academy of Sciences, 614081, 13 Golev str., Perm, Russia
| | - Maria Bochkova
- Institute of Ecology and Genetics of Microorganisms, Perm Federal Research Center of the Ural Branch of the Russian Academy of Sciences, 614081, 13 Golev str., Perm, Russia
| | - Maria Kropaneva
- Institute of Ecology and Genetics of Microorganisms, Perm Federal Research Center of the Ural Branch of the Russian Academy of Sciences, 614081, 13 Golev str., Perm, Russia
| | - Valeria Timganova
- Institute of Ecology and Genetics of Microorganisms, Perm Federal Research Center of the Ural Branch of the Russian Academy of Sciences, 614081, 13 Golev str., Perm, Russia
| | - Svetlana Zamorina
- Department of Biology, Perm State University, 614068, 15 Bukirev str., Perm, Russia; Institute of Ecology and Genetics of Microorganisms, Perm Federal Research Center of the Ural Branch of the Russian Academy of Sciences, 614081, 13 Golev str., Perm, Russia
| | - Mikhail Rayev
- Department of Biology, Perm State University, 614068, 15 Bukirev str., Perm, Russia; Institute of Ecology and Genetics of Microorganisms, Perm Federal Research Center of the Ural Branch of the Russian Academy of Sciences, 614081, 13 Golev str., Perm, Russia
| |
Collapse
|
5
|
Marques MR, Choo Q, Ashtikar M, Rocha TC, Bremer-Hoffmann S, Wacker MG. Nanomedicines - Tiny particles and big challenges. Adv Drug Deliv Rev 2019; 151-152:23-43. [PMID: 31226397 DOI: 10.1016/j.addr.2019.06.003] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Revised: 06/10/2019] [Accepted: 06/14/2019] [Indexed: 02/08/2023]
Abstract
After decades of research, nanotechnology has been used in a broad array of biomedical products including medical devices, drug products, drug substances, and pharmaceutical-grade excipients. But like many great achievements in science, there is a fine balance between the risks and opportunities of this new technology. Some materials and surface structures in the nanosize range can exert unexpected toxicities and merit a more detailed safety assessment. Regulatory agencies such as the United States Food and Drug Administration or the European Medicines Agency have started dealing with the potential risks posed by nanomaterials. Considering that a thorough characterization is one of the key aspects of controlling such risks this review presents the regulatory background of nanosafety assessment and provides some practical advice on how to characterize nanomaterials and drug formulations. Further, the challenges of how to maintain and monitor pharmaceutical quality through a highly complex production processes will be discussed.
Collapse
|
6
|
Feczkó T, Piiper A, Pleli T, Schmithals C, Denk D, Hehlgans S, Rödel F, Vogl TJ, Wacker MG. Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques. Pharmaceutics 2019; 11:pharmaceutics11100489. [PMID: 31548500 PMCID: PMC6835296 DOI: 10.3390/pharmaceutics11100489] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2019] [Revised: 09/06/2019] [Accepted: 09/18/2019] [Indexed: 12/13/2022] Open
Abstract
Today, efficient delivery of sorafenib to hepatocellular carcinoma remains a challenge for current drug formulation strategies. Incorporating the lipophilic molecule into biocompatible and biodegradable theranostic nanocarriers has great potential for improving the efficacy and safety of cancer therapy. In the present study, three different technologies for the encapsulation of sorafenib into poly(d,l-lactide-co-glycolide) and polyethylene glycol-poly(d,l-lactide-co-glycolide) copolymers were compared. The particles ranged in size between 220 and 240 nm, with encapsulation efficiencies from 76.1 ± 1.7% to 69.1 ± 10.1%. A remarkable maximum drug load of approximately 9.0% was achieved. Finally, a gadolinium complex was covalently attached to the nanoparticle surface, transforming the nanospheres into theranostic devices, allowing their localization using magnetic resonance imaging. The manufacture of sorafenib-loaded nanoparticles alongside the functionalization of the particle surface with gadolinium complexes resulted in a highly efficacious nanodelivery system which exhibited a strong magnetic resonance imaging signal, optimal stability features, and a sustained release profile.
Collapse
Affiliation(s)
- Tivadar Feczkó
- Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudosok krt. 2., H-1117 Budapest, Hungary
- Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, Egyetem u. 2., H-8200 Veszprém, Hungary
- Department of Medicine 1, University Hospital Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany; (A.P.); (T.P.); (C.S.); (D.D.)
- Correspondence: ; Tel.: +36-88-624000/3508
| | - Albrecht Piiper
- Department of Medicine 1, University Hospital Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany; (A.P.); (T.P.); (C.S.); (D.D.)
| | - Thomas Pleli
- Department of Medicine 1, University Hospital Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany; (A.P.); (T.P.); (C.S.); (D.D.)
| | - Christian Schmithals
- Department of Medicine 1, University Hospital Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany; (A.P.); (T.P.); (C.S.); (D.D.)
| | - Dominic Denk
- Department of Medicine 1, University Hospital Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany; (A.P.); (T.P.); (C.S.); (D.D.)
| | - Stephanie Hehlgans
- Department of Radiotherapy and Oncology, University Hospital Frankfurt am Main, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany; (S.H.); (F.R.)
| | - Franz Rödel
- Department of Radiotherapy and Oncology, University Hospital Frankfurt am Main, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany; (S.H.); (F.R.)
| | - Thomas J. Vogl
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany;
| | - Matthias G. Wacker
- Department of Pharmacy, National University of Singapore, 6 Science Drive 2, Singapore 117546, Singapore;
| |
Collapse
|
7
|
Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice. Proc Natl Acad Sci U S A 2018; 115:E7758-E7767. [PMID: 30065113 DOI: 10.1073/pnas.1805713115] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Influenza is a persistent threat to public health. Here we report that double-layered peptide nanoparticles induced robust specific immunity and protected mice against heterosubtypic influenza A virus challenges. We fabricated the nanoparticles by desolvating a composite peptide of tandem copies of nucleoprotein epitopes into nanoparticles as cores and cross-linking another composite peptide of four tandem copies of influenza matrix protein 2 ectodomain epitopes to the core surfaces as a coating. Delivering the nanoparticles via dissolvable microneedle patch-based skin vaccination further enhanced the induced immunity. These peptide-only, layered nanoparticles demonstrated a strong antigen depot effect and migrated into spleens and draining (inguinal) lymph nodes for an extended period compared with soluble antigens. This increased antigen-presentation time correlated with the stronger immune responses in the nanoparticle-immunized group. The protection conferred by nanoparticle immunization was transferable by passive immune serum transfusion and depended partially on a functional IgG receptor FcγRIV. Using a conditional cell depletion, we found that CD8+ T cells were involved in the protection. The immunological potency and stability of the layered peptide nanoparticles indicate applications for other peptide-based vaccines and peptide drug delivery.
Collapse
|
8
|
Janas C, Mast MP, Kirsamer L, Angioni C, Gao F, Mäntele W, Dressman J, Wacker MG. The dispersion releaser technology is an effective method for testing drug release from nanosized drug carriers. Eur J Pharm Biopharm 2017; 115:73-83. [PMID: 28213179 DOI: 10.1016/j.ejpb.2017.02.006] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Revised: 02/09/2017] [Accepted: 02/12/2017] [Indexed: 10/20/2022]
Abstract
The dispersion releaser (DR) is a dialysis-based setup for the analysis of the drug release from nanosized drug carriers. It is mounted into dissolution apparatus2 of the United States Pharmacopoeia. The present study evaluated the DR technique investigating the drug release of the model compound flurbiprofen from drug solution and from nanoformulations composed of the drug and the polymer materials poly (lactic acid), poly (lactic-co-glycolic acid) or Eudragit®RSPO. The drug loaded nanocarriers ranged in size between 185.9 and 273.6nm and were characterized by a monomodal size distribution (PDI<0.1). The membrane permeability constants of flurbiprofen were calculated and mathematical modeling was applied to obtain the normalized drug release profiles. For comparing the sensitivities of the DR and the dialysis bag technique, the differences in the membrane permeation rates were calculated. Finally, different formulation designs of flurbiprofen were sensitively discriminated using the DR technology. The mechanism of drug release from the nanosized carriers was analyzed by applying two mathematical models described previously, the reciprocal powered time model and the three parameter model.
Collapse
Affiliation(s)
- Christine Janas
- Goethe University, Institute of Pharmaceutical Technology, D-60438 Frankfurt, Germany
| | - Marc-Phillip Mast
- Goethe University, Institute of Pharmaceutical Technology, D-60438 Frankfurt, Germany
| | - Li Kirsamer
- Goethe University, Institute for Biophysics, D-60438 Frankfurt, Germany
| | - Carlo Angioni
- Goethe University, Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, D-60590 Frankfurt, Germany
| | - Fiona Gao
- Goethe University, Institute of Pharmaceutical Technology, D-60438 Frankfurt, Germany
| | - Werner Mäntele
- Goethe University, Institute for Biophysics, D-60438 Frankfurt, Germany
| | - Jennifer Dressman
- Goethe University, Institute of Pharmaceutical Technology, D-60438 Frankfurt, Germany
| | - Matthias G Wacker
- Goethe University, Institute of Pharmaceutical Technology, D-60438 Frankfurt, Germany; Fraunhofer-Institute for Molecular Biology and Applied Ecology, Department of Pharmaceutical Technology and Nanosciences, D-60438 Frankfurt, Germany.
| |
Collapse
|
9
|
Geh KJ, Hubert M, Winter G. Optimisation of one-step desolvation and scale-up of gelatine nanoparticle production. J Microencapsul 2016; 33:595-604. [PMID: 27556342 DOI: 10.1080/02652048.2016.1228706] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Gelatine nanoparticles (GNPs) are biodegradable and biocompatible drug delivery systems with excellent clinical performances. A two-step desolvation is commonly used for their preparation, although this methodology has several shortcomings: lack of reproducibility, small scales and low yields. A straightforward and more consistent GNP preparation approach is presented here focusing on the development of a one-step desolvation with the use of a commercially available gelatine type. Controlled stirring conditions and ultrafiltration are used to achieve large-scale production of nanoparticles of up to 2.6 g per batch. Particle size distributions are conserved and comparable to those determined for two-step desolvation on small scale. Additionally, a range of cross-linking agents is examined for their effectiveness in stabilising GNPs as an alternative to glutaraldehyde. Glyceraldehyde demonstrated outstanding properties, which led to high colloidal stability. This approach optimises the manufacturing process and the scale-up of the production capacity, providing a clear potential for future applications.
Collapse
Affiliation(s)
- Katharina J Geh
- a Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics , Ludwig-Maximilians Universität München , Munich , Germany
| | - Madlen Hubert
- a Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics , Ludwig-Maximilians Universität München , Munich , Germany
| | - Gerhard Winter
- a Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics , Ludwig-Maximilians Universität München , Munich , Germany
| |
Collapse
|
10
|
Kanoujia J, Singh M, Singh P, Parashar P, Tripathi CB, Arya M, Saraf SA. Genipin crosslinked soy-whey based bioactive material for atorvastatin loaded nanoparticles: preparation, characterization and in vivo antihyperlipidemic study. RSC Adv 2016. [DOI: 10.1039/c6ra16830b] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Lipid lowering potential of soy protein isolate and whey protein concentrate as novel nanomaterial for atorvastatin nanoparticles.
Collapse
Affiliation(s)
- Jovita Kanoujia
- Department of Pharmaceutical Sciences
- Babasaheb Bhimrao Ambedkar University, (A Central University)
- Lucknow
- India-226025
| | - Mahendra Singh
- Department of Pharmaceutical Sciences
- Babasaheb Bhimrao Ambedkar University, (A Central University)
- Lucknow
- India-226025
| | - Pooja Singh
- Department of Pharmaceutical Sciences
- Babasaheb Bhimrao Ambedkar University, (A Central University)
- Lucknow
- India-226025
| | - Poonam Parashar
- Department of Pharmaceutical Sciences
- Babasaheb Bhimrao Ambedkar University, (A Central University)
- Lucknow
- India-226025
| | - Chandra Bhusan Tripathi
- Department of Pharmaceutical Sciences
- Babasaheb Bhimrao Ambedkar University, (A Central University)
- Lucknow
- India-226025
| | - Malti Arya
- Department of Pharmaceutical Sciences
- Babasaheb Bhimrao Ambedkar University, (A Central University)
- Lucknow
- India-226025
| | - Shubhini A. Saraf
- Department of Pharmaceutical Sciences
- Babasaheb Bhimrao Ambedkar University, (A Central University)
- Lucknow
- India-226025
| |
Collapse
|
11
|
Villa Nova M, Janas C, Schmidt M, Ulshoefer T, Gräfe S, Schiffmann S, de Bruin N, Wiehe A, Albrecht V, Parnham MJ, Luciano Bruschi M, Wacker MG. Nanocarriers for photodynamic therapy-rational formulation design and medium-scale manufacture. Int J Pharm 2015; 491:250-60. [PMID: 26123822 DOI: 10.1016/j.ijpharm.2015.06.024] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Revised: 06/08/2015] [Accepted: 06/14/2015] [Indexed: 01/27/2023]
Abstract
The development and manufacture of novel nanocarriers for drug delivery has proved challenging with regards to scale-up and pharmaceutical quality. Polymeric nanocarriers composed of poly(lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-PEG) were prepared and the photosensitizer meso-tetrakis(3-hydroxyphenyl) chlorin (mTHPC) was effectively encapsulated. Furthermore, the interplay of various process and formulation parameters and their impact on the most important product specifications were investigated by using a factorial design and a central composite design in a microfluidic manufacturing process. These nanoparticles for intravenous administration with a size of 97 ± 0.13 nm, narrow size distribution, and an encapsulation efficiency of more than 80% were produced at high throughput. In vitro stability and in vitro drug release testing were applied for quality control purposes. Finally, the toxicity of the photosensitizer was tested in vitro. The cytotoxicity was successfully reduced while the efficacy of the formulation was maintained. First observations using in vivo imaging suggest effective distribution of the nanocarrier system after injection into rodents. Thus, further in vivo testing of the beneficial effects of nanoencapsulation into the matrix system and its formulation will be considered for the delivery of mTHPC to tumor tissues during photodynamic therapy.
Collapse
Affiliation(s)
- Mônica Villa Nova
- Laboratory of R&D of Drug Delivery Systems, Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, State University of Maringá, Av. Colombo, 5790, Maringá, Paraná, Brazil
| | - Christine Janas
- Institute of Pharmaceutical Technology, Goethe University, 60438 Frankfurt (Main), Germany
| | - Mike Schmidt
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Project group for Translational Medicine & Pharmacology (TMP), 60596 Frankfurt/ Main, Germany
| | - Thomas Ulshoefer
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Project group for Translational Medicine & Pharmacology (TMP), 60596 Frankfurt/ Main, Germany
| | - Susanna Gräfe
- biolitec research GmbH, Otto-Schott-Str. 15, 07745 Jena, Germany
| | - Susanne Schiffmann
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Project group for Translational Medicine & Pharmacology (TMP), 60596 Frankfurt/ Main, Germany
| | - Natasja de Bruin
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Project group for Translational Medicine & Pharmacology (TMP), 60596 Frankfurt/ Main, Germany
| | - Arno Wiehe
- biolitec research GmbH, Otto-Schott-Str. 15, 07745 Jena, Germany
| | - Volker Albrecht
- biolitec research GmbH, Otto-Schott-Str. 15, 07745 Jena, Germany
| | - Michael J Parnham
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Project group for Translational Medicine & Pharmacology (TMP), 60596 Frankfurt/ Main, Germany
| | - Marcos Luciano Bruschi
- Laboratory of R&D of Drug Delivery Systems, Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, State University of Maringá, Av. Colombo, 5790, Maringá, Paraná, Brazil
| | - Matthias G Wacker
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Project group for Translational Medicine & Pharmacology (TMP), 60596 Frankfurt/ Main, Germany.
| |
Collapse
|
12
|
Taheri A, Razavi SMA. Fabrication of Cress Seed Gum Nanoparticles, an Anionic Polysaccharide, Using Desolvation Technique: an Optimization Study. BIONANOSCIENCE 2015. [DOI: 10.1007/s12668-015-0169-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Peralta DV, Heidari Z, Dash S, Tarr MA. Hybrid paclitaxel and gold nanorod-loaded human serum albumin nanoparticles for simultaneous chemotherapeutic and photothermal therapy on 4T1 breast cancer cells. ACS APPLIED MATERIALS & INTERFACES 2015; 7:7101-7111. [PMID: 25768122 DOI: 10.1021/acsami.5b00858] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The use of human serum albumin nanoparticles (HSAPs) as a drug carrier system for cancer treatment has proven successful through current marketable clinical formulations. Despite this success, there is a current lack of multifunctional HSAPs, which offer combinational therapies of more than one proven technique. Gold nanorods (AuNRs) have also shown medicinal promise due to their photothermal therapy capabilities. In this study, a desolvation and cross-linking approach was employed to successfully encapsulate gold nanorods into HSAPs simultaneously with the chemotherapeutic drug paclitaxel (PAC); forming PAC-AuNR-HSAPs with desirable overall particle sizes of 299 ± 6 nm. The loading efficiency of paclitaxel into PAC-AuNR-HSAPs reached up to 3 μg PAC/mg HSA. The PAC-AuNR-HSAPs experienced photothermal heating; with the bulk particle solution reaching up to 46 °C after 15 min of near-IR laser exposure. This heat increase marked the successful attainment of the temperature necessary to cause severe cellular hyperthermia and necrosis. The encasement strategy facilitated a colloidal hybrid treatment system capable of enhanced permeability and retention effects, photothermal ablation of cancer cells, and release of the active paclitaxel of up to 188 ng (from PAC-AuNR-HSAPs created with 30 mg HSA) in a single 15 min irradiation session. When treated with PAC-AuNR-HSAPs containing 20 μg PAC/mL particle solution, 4T1 mouse breast cancer cells experienced ∼82% cell death without irradiation and ∼94% cell death after just one irradiation session. The results for PAC-AuNR-HSAPs were better than that of free PAC, which only killed ∼77% of the cells without irradiation and ∼80% with irradiation. The hybrid particle system also lends itself to future customizable external functionalities via conjugated targeting ligands, such as antibodies. Internal entrapment of patient tailored medication combinations are also possible with this combination treatment platform, which may result in improved quality of life for those undergoing treatment.
Collapse
Affiliation(s)
- Donna V Peralta
- †Department of Chemistry and Advanced Materials Research Institute, University of New Orleans, New Orleans, Louisiana 70148, United States
| | | | - Srikanta Dash
- §Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, United States
| | - Matthew A Tarr
- †Department of Chemistry and Advanced Materials Research Institute, University of New Orleans, New Orleans, Louisiana 70148, United States
| |
Collapse
|
14
|
Efficient Delivery of Therapeutic Agents by Using Targeted Albumin Nanoparticles. ADVANCES IN PROTEIN CHEMISTRY AND STRUCTURAL BIOLOGY 2015; 98:121-43. [DOI: 10.1016/bs.apcsb.2014.11.002] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|
15
|
Wacker MG, Altinok M, Urfels S, Bauer J. Nanoencapsulation of ultra-small superparamagnetic particles of iron oxide into human serum albumin nanoparticles. BEILSTEIN JOURNAL OF NANOTECHNOLOGY 2014; 5:2259-2266. [PMID: 25551054 PMCID: PMC4273279 DOI: 10.3762/bjnano.5.235] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Accepted: 11/11/2014] [Indexed: 06/04/2023]
Abstract
Human serum albumin nanoparticles have been utilized as drug delivery systems for a variety of medical applications. Since ultra-small superparamagnetic particles of iron oxide (USPIO) are used as contrast agents in magnetic resonance imaging, their encapsulation into the protein matrix enables the synthesis of diagnostic and theranostic agents by surface modification and co-encapsulation of active pharmaceutical ingredients. The present investigation deals with the surface modification and nanoencapsulation of USPIO into an albumin matrix by using ethanolic desolvation. Particles of narrow size distribution and with a defined particle structure have been achieved.
Collapse
Affiliation(s)
- Matthias G Wacker
- Fraunhofer-Institute for Molecular Biology and Applied Ecology, Project group for Translational Research and Pharmacology, D-60438 Frankfurt, Germany
| | - Mahmut Altinok
- Goethe-University, Institute of Pharmaceutical Technology, D-60438 Frankfurt, Germany
| | - Stephan Urfels
- Technische Universität Darmstadt, Technical Chemistry, D-64287 Darmstadt, Germany
| | | |
Collapse
|
16
|
Bridging Laboratory and Large Scale Production: Preparation and In Vitro-Evaluation of Photosensitizer-Loaded Nanocarrier Devices for Targeted Drug Delivery. Pharm Res 2014; 32:1714-26. [DOI: 10.1007/s11095-014-1569-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Accepted: 11/04/2014] [Indexed: 01/12/2023]
|
17
|
Peralta DV, He J, Wheeler DA, Zhang JZ, Tarr MA. Encapsulating gold nanomaterials into size-controlled human serum albumin nanoparticles for cancer therapy platforms. J Microencapsul 2014; 31:824-31. [DOI: 10.3109/02652048.2014.940012] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
18
|
Dadparvar M, Wagner S, Wien S, Worek F, von Briesen H, Kreuter J. Freeze-drying of HI-6-loaded recombinant human serum albumin nanoparticles for improved storage stability. Eur J Pharm Biopharm 2014; 88:510-7. [PMID: 24995841 DOI: 10.1016/j.ejpb.2014.06.008] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2014] [Revised: 06/11/2014] [Accepted: 06/14/2014] [Indexed: 10/25/2022]
Abstract
Severe intoxications with organophosphates require the immediate administration of atropine in combination with acetyl cholinesterase (AChE) reactivators such as HI-6. Although this therapy regimen enables the treatment of peripheral symptoms, the blood-brain barrier (BBB) restricts the access of the hydrophilic antidotes to the central nervous system which could lead to a fatal respiratory arrest. Therefore, HI-6-loaded albumin nanoparticles were previously developed to enhance the transport across this barrier and were able to reactivate organophosphate-(OP)-inhibited AChE in an in vitro BBB model. Since HI-6 is known to be moisture-sensitive, the feasibility of freeze-drying of the HI-6-loaded nanoparticles was investigated in the present study using different cryo- and lyoprotectants at different concentrations. Trehalose and sucrose (3%, w/v)-containing formulations were superior to mannitol concerning the physicochemical parameters of the nanoparticles whereas trehalose-containing samples were subject of a prolonged storage stability study at temperatures between -20°C and +40°C for predetermined time intervals. Shelf-life computations of the freeze-dried HI-6 nanoparticle formulations revealed a shelf-life time of 18 months when stored at -20°C. The formulations' efficacy was proven in vitro by reactivation of OP-inhibited AChE after transport over a porcine brain capillary endothelial cell layer model.
Collapse
Affiliation(s)
- Miriam Dadparvar
- Institute of Pharmaceutical Technology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
| | - Sylvia Wagner
- Department of Cell Biology & Applied Virology, Fraunhofer Institute for Biomedical Engineering, St. Ingbert, Germany
| | - Sascha Wien
- Department of Cell Biology & Applied Virology, Fraunhofer Institute for Biomedical Engineering, St. Ingbert, Germany
| | - Franz Worek
- Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany
| | - Hagen von Briesen
- Department of Cell Biology & Applied Virology, Fraunhofer Institute for Biomedical Engineering, St. Ingbert, Germany
| | - Jörg Kreuter
- Institute of Pharmaceutical Technology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
| |
Collapse
|
19
|
Wacker MG. Nanotherapeutics—Product Development Along the “Nanomaterial” Discussion. J Pharm Sci 2014; 103:777-84. [DOI: 10.1002/jps.23879] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2013] [Revised: 01/08/2014] [Accepted: 01/08/2014] [Indexed: 01/05/2023]
|
20
|
Zhao S, Wang W, Huang Y, Fu Y, Cheng Y. Paclitaxel loaded human serum albumin nanoparticles stabilized with intermolecular disulfide bonds. MEDCHEMCOMM 2014. [DOI: 10.1039/c4md00200h] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A self-cross-link strategy was adopted to form inter-protein disulfide crosslinks with albumin's own thiol groups. PTX was further entrapped non-covalently in the HSA matrix to form paclitaxel loaded HSA nanoparticles (PTX-HSA-NPs).
Collapse
Affiliation(s)
- Shufang Zhao
- Department of Chemical Engineering
- Tsinghua University
- Beijing 100084, P. R. China
| | - Wentan Wang
- Department of Chemical Engineering
- Tsinghua University
- Beijing 100084, P. R. China
| | - Yanbin Huang
- Department of Chemical Engineering
- Tsinghua University
- Beijing 100084, P. R. China
| | - Yuhang Fu
- Department of Chemical Engineering
- Tsinghua University
- Beijing 100084, P. R. China
| | - Yi Cheng
- Department of Chemical Engineering
- Tsinghua University
- Beijing 100084, P. R. China
| |
Collapse
|
21
|
Wacker M. Nanocarriers for intravenous injection--the long hard road to the market. Int J Pharm 2013; 457:50-62. [PMID: 24036012 DOI: 10.1016/j.ijpharm.2013.08.079] [Citation(s) in RCA: 111] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2013] [Revised: 08/27/2013] [Accepted: 08/28/2013] [Indexed: 12/19/2022]
Abstract
Nanodispersed drug delivery systems for the intravenous injection have successfully overcome the hurdle of drug approval in the European Union and the United States. Although there is a need for highly advanced nanocarrier devices they have not been the result of a rational formulation design but were developed as stand-alone products in a long chain of case-by-case studies. This review focuses on aspects in development, composition, and manufacture of these innovative dosage forms that are relevant for the translation into new drug products.
Collapse
Affiliation(s)
- Matthias Wacker
- Institute of Pharmaceutical Technology, Goethe University, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany.
| |
Collapse
|
22
|
Yedomon B, Fessi H, Charcosset C. Preparation of Bovine Serum Albumin (BSA) nanoparticles by desolvation using a membrane contactor: a new tool for large scale production. Eur J Pharm Biopharm 2013; 85:398-405. [PMID: 23811438 DOI: 10.1016/j.ejpb.2013.06.014] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2013] [Revised: 05/27/2013] [Accepted: 06/10/2013] [Indexed: 11/29/2022]
Abstract
Albumin nanoparticles are attractive drug delivery systems as they can be prepared under soft conditions and incorporate several kinds of molecules. The aim of this study was to upscale the desolvation process for preparing Bovine Serum Albumin (BSA) nanoparticles using a membrane contactor. At a first step, the BSA nanoparticles were prepared at small scale using a syringe pump. BSA nanoparticles of 139 nm in size, with a polydispersity index of 0.046, were obtained at the optimal conditions: pH 8.2, 100 mg mL(-1) BSA albumin solution (2 mL), and 1 mL min(-1) flow rate of ethanol addition (8 mL). The upscaling with a membrane contactor was achieved by permeating ethanol through the pores of a Shirasu Porous Glass (SPG Technology Co., Japan) membrane and circulating the aqueous phase tangentially to the membrane surface. By increasing the pressure of the ethanol from 1 to 2.7 bars, a progressive decrease in nanoparticle size was obtained with a high nanoparticles yield (around 94-96%). In addition, the flow rate of the circulating phase did not affect the BSA nanoparticle characteristics. At the optimal conditions (pH 8.2, 100 mg mL(-1) BSA albumin solution, pressure of ethanol 2.7 bars, flow rate of the circulating phase 30.7 mL s(-1)), the BSA nanoparticles showed similar characteristics to those obtained with the syringe pump. Large batches of BSA nanoparticles were prepared up to 10 g BSA. The BSA nanoparticles were stable at least during 2 months at 4 °C, and their characteristics were reproducible. It was then concluded that the membrane contactor technique could be a suitable method for the preparation of albumin nanoparticles at large scale with properties similar to that obtained at small scale.
Collapse
Affiliation(s)
- B Yedomon
- Laboratoire d'Automatique et de Génie des Procédés (LAGEP), Université Claude Bernard Lyon 1, Villeurbanne Cedex, France
| | | | | |
Collapse
|
23
|
von Storp B, Engel A, Boeker A, Ploeger M, Langer K. Albumin nanoparticles with predictable size by desolvation procedure. J Microencapsul 2012; 29:138-46. [DOI: 10.3109/02652048.2011.635218] [Citation(s) in RCA: 92] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|